Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

BioMedWire Spotlight Company

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

NRx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

BioMedWire Spotlight Company

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

Quantum BioPharma Ltd. is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd™, a novel alcohol detoxification beverage.

BioMedWire Spotlight Company

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors.

BioMedWire Spotlight Company

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company's development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

BioMedWire Spotlight Company

Annovis Bio Inc. (NYSE: ANVS)

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

BioMedWire Spotlight Company

Aditxt Inc. (NASDAQ: ADTX)

Aditxt Inc. is a innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

BioMedWire Spotlight Company

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN)

Cybin Inc. is a clinical-stage biopharmaceutical company focused on progressing psychedelics to therapeutics, offering a new standard of care for mental health disorders and improving patient outcomes. The company is led by a team of leading scientific and industry experts with deep roots in biotech, psychedelics, and mental health, to translate top-tier science into potential best-in-class therapeutics.

BioMedWire Spotlight Company

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

BioMedWire Client Partners

Official NewsWire Relationships

BIO Informa

DGE Dynamic Global Events

DTC Healthcare Conference

Kiasco Reasearch

Nexus Conferences

Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

BioMedWire

1108 Lavaca St
Suite 110-BMW
Austin, TX 78701
(512) 354-7000

Company Search

Get Quote

Site Search

Copyright © . BioMedWire / 1108 Lavaca St Suite 110-BMW Austin, TX 78701 (512) 354-7000 / Disclaimers